



Chronic Lymphocytic Leukemia (CLL): Optimal Integration and Side Effect Management of Novel Therapies

Saturday, August 14, 2021, 9.00 AM – 1.30 PM AST

Chair: Javier Pinilla, MD, PhD

AGENDA

Time (AST)	Topic
Program 1: Focus on Oncologists and Hematologists (9.00 AM – 11.00 AM)	
9.00 AM – 9.15 AM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • ARS questions
9.15 AM – 10.00 AM (45 min)	Optimal Integration and Side Effect Management of Novel Therapies in CLL <i>Javier Pinilla, MD, PhD</i> <ul style="list-style-type: none"> • Overview of current data <ul style="list-style-type: none"> – BTKi therapy, differentiation of available options, and patient selection <ul style="list-style-type: none"> ▪ Patient factors guiding therapy choice ▪ Setting expectations and patient counseling prior to initiation of therapy ▪ Latest trial data and emerging therapies – BTKi class AEs <ul style="list-style-type: none"> ▪ Prevention of AEs ▪ Monitoring and management of AEs and toxicities ▪ Dosing modifications vs discontinuation for AEs ▪ Strategies for optimal adherence to prescribed BTKi therapies – BTKi and other (targeted) therapies (BCL2-targeted therapy) <ul style="list-style-type: none"> ▪ Role of fixed-duration treatment vs treatment until progression ▪ CAPTIVATE trial – Chemotherapy vs oral agents
10.00 AM – 10.45 AM (45 min)	Moderated Discussion
10.45 AM – 11.00 AM (15 min)	Key Takeaways and Meeting Evaluation
11.00 AM – 11.30 AM (30 min)	Break

Program 2: Focus on Nurses (11.30 AM – 1.30 PM)	
11.30 AM – 11.45 AM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • ARS questions
11.45 AM – 12.05 PM (20 min)	Novel Therapies in CLL <i>Javier Pinilla, MD, PhD</i> <ul style="list-style-type: none"> • Overview of current data <ul style="list-style-type: none"> – Chemotherapy vs oral agents – BTKi and other (targeted) therapies (BCL2-targeted therapy) <ul style="list-style-type: none"> ▪ Role of fixed-duration treatment vs treatment until progression ▪ CAPTIVATE trial – BTKi therapy, differences and patient selection <ul style="list-style-type: none"> ▪ Patient factors guiding therapy choice
12.05 AM – 12.30 PM (25 min)	Side Effect and Patient Management With Novel Therapies in CLL <i>Kelly Garvin, BSN, RN, OCN</i> <ul style="list-style-type: none"> • Nursing perspectives <ul style="list-style-type: none"> – BTKi class AEs <ul style="list-style-type: none"> ▪ Monitoring and management of AEs and toxicities ▪ Prevention of AEs ▪ Dosing modifications vs discontinuation for AEs ▪ Strategies for optimal adherence to prescribed BTKi therapies ▪ Setting expectations and patient counseling prior to initiation of therapy
12.30 PM – 1.15 PM (45 min)	Moderated Discussion
1.15 PM – 1.30 PM (15 min)	Key Takeaways and Meeting Evaluation